My reply to the email I just got from Paul R. Please

New Post Public Reply Private Reply Replies (5) Message Board
CDiddy
884
My reply to the email I just got from Paul R.



Please take me off your list

On Tue, Aug 24, 2021, 7:23 PM Paul R <exitpoll@aol.com> wrote:
Dear CytoDyn Inc. stockholders:

First of all, thank you for your support so far.

We truly expect to win this election contest with your help.

We expect the management at CytoDyn to make many attempts to reach out to you prior to the upcoming annual meeting and it could get very confusing as we get close to Oct 28 (the announced annual meeting date). The main point is to vote our proxy on the white card that you will be getting by snail mail or email. Once you vote that white card you can be done as long as you do not fill out anything from the company. Best advice about any material you get from the company: do not respond to after reading. You can never go wrong by filing out any WHITE CARD YOU RECEIVE. Again, if you do fill out any Proxy from the company you will cancel out your vote for us. PLEASE DO NOT FILL OUT ANY PROXY MATERIAL FROM THE COMPANY!

Your vote is important, no matter how many shares of CytoDyn, Inc. ("CytoDyn" or "CYDY" you own. On behalf of the CYDY Investor Group, we recommend that stockholders vote on our WHITE proxy card or voting instruction form (the "WHITE CARD" that you receive “FOR ALL” of the Investor Group's highly qualified and very experienced nominees for the CYDY board.

You may vote by phone or Internet by following the instructions on the WHITE CARD that you receive. If you received your proxy card or voting instruction form by mail, you can also sign and return it in the enveloped enclosed with the WHITE CARD.

IF YOU HAVE ANY QUESTIONS AT ALL we encourage you to contact our proxy solicitor, Okapi Partners LLC, at +1 844-202-7428 (Toll Free).

Since this election is a contested proxy solicitation, if you do not give voting instructions to your broker, bank, or other custodian, your broker, bank, or other custodian will not be able to vote your shares with respect to the election of CYDY directors.

We urge you to instruct your broker, bank, or other custodian to vote your shares on the WHITE CARD.

We expect CytoDyn management will also send you proxy materials (when filed and available for distribution) and we urge you to discard any such materials.



In the event you make a mistake and return a proxy card or voting instruction form sent to you by CYDY management or current board, you can change your vote, by calling our Proxy company Okapi Partners LLC, at +1 844-202-7428 (Toll Free).



Only your latest-dated proxy card will count, so voting any card other than the WHITE CARD may change your vote.

Hope this note is helpful.

Please fill out our White Proxy and return immediately.

Thanks again for your support and help.

Sincerely,

PAUL R.

P.S. Tomorrow I will be sending you an email requesting the name of your brokers that hold your shares as well as asking you the number of shares you own and have or will vote. It is strictly for our Proxy firm to check with all the brokers to make sure all our shares have been voted.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Monetary Metals' Bold $38M Gold Bond: A Strategic Leap

Updated Category News Views 20

A Golden Opportunity in Uncertain Times Monetary Metals just pulled a rabbit outta the hat with this $38 million gold bond. That’s tripling the size from their 2024 offering. Normally, I'm skeptical about flashy bond numbers, but there's a glint of genius here. In a world teetering on the brink of financial chaos, investors are itching for something solid. And gold?...

Continue Reading
Ericsson Executes Aggressive $54M Share Buyback

Updated Category News Views 62

Digging Into Ericsson's Latest Buyback Getting straight to brass tacks, the recent maneuver by Ericsson (SE0000108656)—snapping back 500,000 shares from October 26 to October 30, 2026—raised more than a few eyebrows in the financial alleys. Shelling out SEK 54.46 million in less than a week is no small potatoes, but it’s all part of a grander financial ballet...

Continue Reading
ABVC BioPharma Raises $3.39M in Private Placement

Updated Category News Views 0

Dollar Signs and Big Plans: ABVC's Private Placement ABVC BioPharma just bagged $3.39 million through a private placement of senior convertible promissory notes. This ain’t your average financing move, folks. We’re talking original issue discount notes at a hefty 17.5%, maturing by June 2027. This deal takes the cake for today's big plays. Why This Matters to...

Continue Reading
Julie Boland's Strategic Move to Deere's Board

Updated Category News Views 13

Deere & Company Expands Leadership with Boland Out of the blue, Deer & Company (NYSE: DE) decided to shake things up by adding Julie Boland, the former U.S. honcho at Ernst & Young LLP, to their board. Now, when Deere gets a leader with her pedigree, there’s more than a whiff of strategy at play. Let’s unpack why Deere's pulling the trigger on this boardroom shift....

Continue Reading
Good Springs Earns Spot on Inc.'s 2026 Founder List

Updated Category News Views 5

There's a badge of honor in the investment world that's not about the dollars and cents pouring in—it's about having founders trust you to take care of their business babies. Good Springs Capital just snagged one by being named to Inc.'s 2026 Founder-Friendly Investors list. Now, if you're thinking this is just some fancy accolade, let's chew over the real nuggets here....

Continue Reading
IntelliGenome Partners with NL Diagnóstica for TB Battle

Updated Category News Views 30

Breaking New Ground in Tuberculosis Detection When IntelliGenome, a Houston-based developer of CRISPR-based diagnostic tech, teams up with São Paulo's veteran player NL Diagnóstica, you know they're onto something game-changing. This partnership is all about taking the fight against tuberculosis in Brazil to new heights with their CRISPR-Dx™ diagnostic platform. Not...

Continue Reading
Skanska's Bold CZK 2.2B Prague Venture: What's Brewing?

Updated Category News Views 40

Skanska Rolls the Dice with CZK 2.2 Billion We got Skanska pushing forward with a beefy CZK 2.2 billion investment, translating to about SEK 1 billion, into a new residential phase right in the heart of Prague. It's part of the grand Emil Kolben District project, tasked with blending modern living with low-energy savvy in a city that's slowly shrugging off its industrial...

Continue Reading
Young Talent Tackles IVF & Air Pollution Research

Updated Category News Views 24

Rookie Researcher: Jeffrey's Bold Leap at ASRM 2026 Teenagers typically have their heads buried in textbooks, but Jeffrey Huang's got his eyes set on something bigger. This high school junior from Taipei American School leaped onto the international stage at the American Society for Reproductive Medicine (ASRM) 2026, carrying a scientific study centred on a critical...

Continue Reading
HARIBO Unveils Five Boldly Colored Gummies

Updated Category News Views 0

HARIBO's New Fruity Lineup: A Sweet Adventure Hey folks, grab a bag of these new HARIBO gummies, and you're in for a fruity ride. The candy maker's got a new trick up its sleeve with five whimsical, boldly colored gummies. They've dubbed these little treats single-flavor goodies—each with one distinct shape and taste. It's a marketing move that screams 'collect them...

Continue Reading
Abbott's SonicForce Impresses in Crucial Clinical Trial

Updated Category News Views 285

Breaking Through Cardiac Barriers Never thought I'd see the day when we're literally sending shockwaves through the heart, but here we are. Abbott's makin' waves, quite literally, with its SonicForce™ Coronary Intravascular Lithotripsy (IVL) System. They’ve just dropped some promising 30-day outcomes from the TECTONIC study, which has grabbed the spotlight at the...

Continue Reading

Top 5 Most Recently Viewed Articles

Byrna Technologies Earnings Preview: What Investors Need to Know

Updated Category News Views 143

Byrna Technologies Earnings Preview Byrna Technologies (NASDAQ: BYRN) is preparing to deliver its quarterly earnings report, and anticipation is building among investors regarding its performance. To fully understand what to expect, let’s delve into several key points surrounding this earnings announcement. Analyst Earnings Expectations Analysts are predicting that...

Continue Reading
LifeVantage Celebrates Acquisition of LoveBiome for Growth

Updated Category News Views 319

LifeVantage Announces Acquisition of LoveBiome LifeVantage Corporation, a recognized health and wellness entity, recently completed the acquisition of LoveBiome, an innovative direct sales company specialized in comprehensive microbiome care. This significant move marks a pivotal step for LifeVantage, known for its commitment to enhancing cellular health with products...

Continue Reading
Nabsys Earns ISO 9001:2015 Certification, Elevating Quality Standards

Updated Category News Views 149

Nabsys Achieves ISO 9001:2015 Certification Nabsys 2.0, LLC, known for its advancements in electronic genome mapping technology, has successfully earned ISO 9001:2015 certification. This prestigious certification exemplifies Nabsys' dedication to quality management and their commitment to delivering top-notch products and services. Quality Management and Customer Focus...

Continue Reading
High-Performance Computing Market Growth to USD 92.33 Billion

Updated Category News Views 142

High-Performance Computing Market Size Analysis The High-Performance Computing (HPC) market is poised for remarkable growth, with projections indicating an increase from USD 47.07 billion in 2023 to USD 92.33 billion by 2032. This expansion is fueled by a compound annual growth rate (CAGR) of 7.80% from 2024 to 2032. Market Analysis and Demand Drivers High-performance...

Continue Reading
Metagenomi's Groundbreaking Presentations at Scientific Events

Updated Category News Views 140

Metagenomi's Upcoming Presentations at Leading Scientific Conferences Metagenomi, Inc. (Nasdaq: MGX), a pioneering force in precision genetic medicine, is set to share its innovative approaches and advancements in the field through multiple presentations at highly regarded scientific conferences. The company is dedicated to developing curative therapeutics utilizing its...

Continue Reading